Back to search

Peptide record

TPDB02736

PTP8 Antibacterial Anticancer Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB02736
PTP8
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
FLKLLAGLLKNFA
Physicochemical Analysis
C72H118N16O15
RDCEQHIMPSTWYV
L
1447.83
10.60
2
0
9
+2
-2.99
1.269
165.38
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
2
A
0
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
5
L
2
K
0
M
2
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 5 K: 2 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C72H118N16O15
1447.83
10.60
+2
-2.99
1.269
Free
L
Linear
Free
Antibacterial
Gaegurin
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50=24.58 µg/ml
Anticancer
24.58 µg/mL

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=26.8 µg/ml
Anticancer
26.8 µg/mL

Target

Renal Cancer
293
Renal

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 3 Activity

Activity

IC50
IC50=28.9 µg/ml
Anticancer
28.9 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 4 Activity

Activity

IC50
IC50=30.79 µg/ml
Anticancer
30.79 µg/mL

Target

Liver Cancer
Hep3B
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 5 Activity

Activity

IC50
IC50=32.23 µg/ml
Anticancer
32.23 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 6 Activity

Activity

IC50
Toxicity
26.80±5.52 µg/mL
Cytotoxic
IC50 | 26.80±5.52 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. | Peptides | 2003
Evidence 7 Activity

Activity

IC50
Toxicity
26.80
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs: less than 6% hemolysis at 100 µg/ml | Cytotoxicity: HEK293: IC50=26.80 ± 5.52 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2003 Jul 24(7):945-53.